MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM.

MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3.

MK-3281 is a potent and orally bioavailable inhibitor of HCV NS5B polymerase with IC50 of 6 nM.

MK-3697 is a third insomnia drug, currently being developed by Merck. MK-3697 is a potent and selective Orexin receptor antagonist with Ki = 0.95 nM.

MK-3901 is a potent, selective, orally active P2X3 antagonist with IC50 of 21 nM.

MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM.

MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM.

MK591(Quiflapon sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor.

MK-6169 is a potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 1-33 nM, retains potency against common resistance-associated substitutions in the major genotypes.

MK-6240 is a positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs.

MK-6892 is a highly potential GPR109A agonist with Ki value of 4.0 nM.

MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM.

MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM.

MK-8141 (ACT-077825) is a novel potent, selective, direct Renin inhibitor for the treatment of cardiovascular disorders..

MK-8245 trifluoroacetate is a potent, selective liver-targeted stearoyl-CoA desaturase (SCD) inhibitor with IC50 of 3, 3 and 1 nM for rat, mouse and human SCD1 enzyme, respectively.

MK-8267 (SCH 2047069) is a potent, orally bioavailable, brain penetrant kinesin spindle protein (KSP) inhibitor with EC50 of 3 nM.

MK-8282 is a potent, selective, oral GPR119 agonist with EC50 of 10 and 58 nM for hGPR119 and mGPR119, respectively.

MK-8318 (MK8318) is a potent, selective, orally available CRTh2 receptor antagonist with Ki of 5 nM, shows nM potency in functional assay (cAMP IC50=8 nM, β-Arrestin IC50=3.5 nM.

MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively.

MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively.

MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK

MK-8353 hydrochloride (SCH-900353) is a highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively.

MK-8591 (Islatravir, MK8591, EFdA) is a nucleoside analog that exhibits remarkable potency against wild-type and drug-resistant HIVs, inhibits HIV-1 reverse transcriptase with multiple mechanisms.

MK-8722 is a systemic, Direct Pan-Activator of AMP-Activated Protein Kinase.

MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.

MK-8825 is a highly potent, selective, orally bioavailable CGRP receptor antagonist with Ki of 17 nM for rat CGRP.

MK-9470 is a potent, selective cannabinoid CB1 receptor (CB1R) inverse agonist with IC50 of 0.7 nM, 18F MK-9470 has been developed for use in human brain imaging..

MKC9989 is a specific small molecule inhibitor of IRE1α Rnase (Kd=0.84 uM) with potency against the splicing of XBP1 mRNA (EC50=0.33 uM)..

MKK7-COV-13 (MKK7 Covalen inhibitor 13) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 10 nM, displays >1,000-fold selectivity over MKK4 (IC50>10 uM).

MKK7-COV-3 (MKK7 Covalen inhibitor 3) is a potent, selective, covalent MKK7 inhibitor with in vitro IC50 of 5 nM, displays >1,000-fold selectivity over MKK4 (IC50=7.81 uM), shows EC50 of 1.3 uM for reduction of p-JNK in ICW assays in Beas2B cell line, wit

MKK7-COV-9 (MKK7 Covalen inhibitor 9) is a potent, selective, covalent MKK7 inhibitor, displays >1,000-fold selectivity over MKK4.

MKT-077 (FJ-776) is a highly water-soluble (>200 mg/ml) rhodacyanine dye that exhibits significant antitumor activity, binds to Hsp70 family member, mortalin (mot-2), and abrogates its interactions with p53.

ML 086 is a potent, specific inhibitor of phosphatase PHOSPHO1 with IC50 of 139 nM, with no activity against TNAP (IC50>100 uM).

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

ML 309 is a potent, selective mutant IDH1 R132H inhibitor with IC50 of 96 nM.

ML 604086 (ML604086) is a potent, selective CCR8 inhibitor that inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations with IC50 of 1.3 uM and 1.0 uM respectively in cellular assays.

ML 604440 (ML604440, ML-604440) is a potent, specific and cell permeable proteasome β1i (LMP2) subunit inhibitor.

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML00253764 is a non-peptide, brain penetrant melanocortin MC4 receptor (MC4R) antagonist with IC50 of 0.32, 0.81 and 2.12 uM for MC4, MC3 and MC5 receptors, respectively.

ML090 (ML-090, CCG-44699, Fluoflavin, NSC 179821) is a potent, selecitve inhibitor of NADPH oxidase 1 (NOX1) with IC50 of 90 nM, displays no significant activities against NOX2, 3 and 4 (IC50>10 uM)..

ML104 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML115 is a novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitor (BMMPI), spares the activity of other MMPs including MMP-9.

ML119 (CID1357397.

ML132 (NCGC-00183434, CID-4462093) is a highly potent, selective Caspase 1 inhibitor with IC50 of 0.023 nM, displays >1,000-fold selectivity over a panel of 9 caspases..

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML133 (CID781301) is a potent, selective K(ir)2.1 potassium channel with IC50 of 1.8 uM at pH 7.4 and 290 nM at pH 8.5, respectively.

ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B.

ML-184 (ML184) is a potent, selective GPR55 agonist with EC50 of 263 nM, >120-fold, 83-fold, and 57-fold selectivity against GPR35, CB1 and CB2.

ML-191 is a potent, selective GPR55 antagonist with 160 nM potency for GPR55 and >100-fold selectivity against GPR35, CB1 and CB2.

ML193 (CID 1261822) is a potent, selective GPR55 antagonist with IC50 of 221 nM, shows >27-, >145- and >145-fold selectivity for GPR55 over CB1, GPR35 and CB2, respectively.

ML197 is a potent, selective small molecule inhibitor of Cdc2-like kinases (CLK) and DYRK with IC50 of 96/40/206 nM for CLK1/CLK4/Dyrk1A, respectively.

ML-228 is a hIF pathway activator (EC50 values are 1.23 and 1.4 μM for HRE gene reporter assay and HIF-1α nuclear translocation assay respectively); acts via chelation of iron, independently of PHD.

ML-265 activates tumor-specific PKM2 (EC50 = 92 nM) by binding to the dimer-dimer interface between two subunits of PKM2 and inducing tetramerization.

ML278 is a potent and reversible inhibitor of lipid uptake via SR-BI (scavenger receptor BI) with IC50 of 6 nM.

ML279 is a potent and reversible inhibitor of lipid uptake via SR-BI (scavenger receptor BI) with IC50 of 17 nM.

ML-290 is a potent and orally active relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM.

ML298 is a potent, selective phospholipase PLD2 inhibitor with IC50 of 355 nM, displays >53-fold selectivity over PLD1 (IC50>20 uM).

ML299 is a potent, CNS penetrant, dual phospholipase PLD1/PLD2 probe with IC50 of 6 nM/20 nM, respectively.

ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction.

ML316 is a specific antifungal agent that fungal-selectively inhibits the mitochondrial phosphate carrier Mir1, exhibits potent antifungal activity against the moderatelyazole-resistant C. albicans strain CaCi-2 with MIC of 0.05 ug/ml.

ML350 (CYM 50202) is a highly potent and selective Opioid kappa receptor (OPRK1/KOR) antagonist with IC50 of 9-16 nM.

ML352 (VU-0476201) is a potent, selective choline transporter (CHT) inhibitor with Ki of 92 nM.

ML354 (VU0099704) is a novel potent and selective PAR4 antagonist with IC50 of 140 nM, displays 71-fold selectivity versus PAR-1.

ML358 is a first in class, selective small molecule inhibitor of the SKN-1 pathway with IC50 of 0.24 uM.

ML359 is a small molecule, specific inhibitor of Protein disulfide isomerase (PDI) with IC50 of 250 nM; displays >100-fold selectivity over other thiol isomerases (Erp5, Thioredoxin, Thioredoxin reductase); shows no cytotoxicity in three human cell lines, and some activity in inhibiting platelet aggregation in vitro.

ML368 (SR 9186) is a potent, selective cytochrome P450 enzyme CYP3A4 inhibitor with IC50 of 4 nM (convert testosterone to hydroxytestosterone), displays >2,000-fold selectivity over CYP3A5..

ML372 is a small molecule SMN modulator that increases SMN protein in patient fibroblasts with EC50 of 37 nM; possesses good potency, pharmacokinetics, tolerance, and CNS penetration that are able to increase levels of SMN protein in several model cell lines; increase SMN protein levels in vivo, restore motor function, and prolong survival of SMNΔ7 SMA Mice; improves the righting reflex and extended survival of a severe mouse model of SMA.

ML375 (VU-0483253) is a potent, highly selective M5 NAM with submicromolar potency (human M5 IC50=300 nM, rat M5 IC50=790 nM, M1-M4 IC50> 30 uM), exhibts excellent multispecies PK, high CNS penetration, and enantiospecific inhibition..

ML377 (MLS 0472732) is a small molecule probe that selectively inhibits TAG (Triacylglyceride) accumulation with an IC50 of 1.1 uM, show >45-fold selectivity versus DGAT inhibition and cytotoxicity..

ML378 (CID71710938, JJH-254) is an in vivo active carbamate-based dual inhibitor of lysophospholipase LYPLA1 (APT1) and LYPLA2 (APT2) with IC50 of 122 nM and 245 nM, repectively.

ML379 (CID71576758) is a potent, selective TP53 mutant cancer cells inhibitor with IC50 of 13 nM in sensitive HeLa cells (TP53 mutant).

ML381 (VU0488130) is a highly mAChR subtype selective M5 orthosteric antagonist with IC50/Ki of 450/340 nM for hM5, has no inhibitory activity on hM1-4 (IC50>30 uM).

ML382 is a potent, selective, positive allosteric modulator of Mas-related G protein-coupled receptor X1 (MrgprX1) with EC50 of 190 nM in cell based Ca2+ imaging assay.

ML387 (CID3474778) is a potent, selective NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with IC50 of 19 nM.

ML388 is a potent, selective NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD) inhibitor with IC50 of 34 nM.

ML389 is a highly potent, selective vasopressin receptor 1a (V1a-R) antagonist with IC50 of 40 nM.

ML395 is a potent, selective, allosteric phospholipase D2 (PLD2) inhibitor with cellular IC50 of 360 nM, shows >80-fold selectivity over PLD1 (IC50>30 uM).

ML398 (CID72737723) is a potent, selective, highly brain penetrant dopamine 4 (D4) receptor antagonist with IC50/Ki of 130 nM/60 nM.

ML399 (VU0516340) is a potent and cell penetrant menin-MLL inhibitor with IC50 of 90 nM.

ML401 (CID73169083) is a potent, functional antagonist of EBI-2 (Epstein-Barr virus-induced gene 2) with IC50 of 1 nM, displays activity in a chemotaxis assay (IC50=6 nM).

ML404 is a small molecule inhibitor of mtPTP, inhibits mitochondrial swelling with EC50 of 4.9 nM, shows no effect on mitochondrial coupling at >100 uM.

ML406 is a small molecule Mtb bioA (DAPA synthase) enzyme inhibitor (IC50=30 nM) that shows anti-tubercular activity, dispalys >100-fold selectivity over bioD.

ML-60218 (ML60218) is a broad-spectrum, small molecule inhibitor of RNA polymerase (Pol) III with IC50 of 32 and 27 uM for Saccharomyces cerevisiae and human, respectively.

ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.

MLAF50 is the first small-molecule inhibitor of the REV1 UBM2-Ubiquitin interaction, directly binds to REV1 UBM2 with Kd of 37 uM in SPR assays.

MLi-2 is an a potent, highly selective, orally available, brain penetrant inhibitor of LRRK2 with an IC50 of 0.76 nM.

MLN 3897 is a potent, specific and orally active antagonist of CCR1 with IC50 of 0.8 nM in competition binding assays, 500-fold selectivity over CCR5.

MLN0905 is a mall-molecule and potent inhibitor of PLK1 with IC50 of 2 nM.

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM.

MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization).

MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM; exhibits more than 40-fold selective for Aurora A than Aurora B.

MLR-1023 is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals.

MLS 0038949 is a potent, selective tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 0.19 uM, shows no activity against IAP and PLAP (IC50>100 uM).

MLS 0263839 is a potent, specific inhibitor of the phosphatase PHOSPHO1 with IC50 of 0.14 uM, shows minimal cross-inhibition of TNAP and no inhibition of ENPP1 activity.

MLS-0322825 is a novel potent low-molecular-weight protein tyrosine phosphatase (LMPTP) inhibitor with IC50 of 3.3 uM.

MLS-0437605 is a specific inhibitor of dual-specificity phosphatase 3 (DUSP3) with IC50 of 3.7 uM, 7-fold selectivity over USP22 and >4-fold selectivity over other 10 PTPs (HePTP, TCPTP, PTP1B, etc.).

MLS1082 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MLS-1547 is a G protein-biased agonist of dopamine D2 receptors (EC50 = 0.37 μM in a calcium mobilization assay).

MLS6585 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.

MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes.

MM-589 is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM.

MMBO is a potent, highly selective, brain penetrant, orally active inhibitor of GSK-3 with IC50 of 37 and 53 nM for GSK-3α and GSK-3β, respectively.

MMK7 inhibitor 4a is a potent, sepecific, covalent inhibitor of MMK7, displays >800-fold selectivity over EGFR-WT and EGFR-L858R/T790M.

MMP13-IN-24f is a potent, selective, and orally active MMP-13 inhibitor with IC50/Ki of 0.5/0.19 nM, shows no activity against MMP-1 or TACE (IC50>10 uM).

MMP13-IN-31f is a highly potent, selective, orally bioavailable MMP-13 inhibitor with IC50 of 0.036 nM.

MMP-2/MMP-9 inhibitor II is a dual inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9 (IC50s = 17 and 30 nM, respectively).

MMP-2/MMP-9 inhibitor III is a cyclic peptide inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9 (IC50s = 10-20 μM for both).

MMP3 inhibitor 1 is a potent and highly selective MMP-3 inhibitor with an IC50 of 1 nM.

MMP-3 inhibitor is a peptide inhibitor of matrix metalloproteinase-3 (MMP-3) with a Ki value of 95 nM.

MMPI-1154 is a small molecule MMP-2 inhibitor with IC50 of 10/6.6/13/1.8 uM for MMP1/2/9/13, respectively.

MMRi6 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells..

MMRi64 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells.

MMSET-IN-1 is a potent, selective epigenetic oncogene MMSET (aka NSD2 or WHSC1) inhibitor with Ki/IC50 of 1.6/3.3 uM.

MMV390048 is a novel potent Plasmodium PI4K inhibitor with IC50 of 28 nM against intraerythrocytic life cycle stages of P. falciparum (NF54 drug-sensitive strain).

MMV-667492 (MMV 667492, MMV667492) is a novel potent Ezrin inhibitor with Kd of 29.4 nM.

MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression

MN30 (Methyl-3,4-dephostatin, APOBEC3G inhibitor MN30) is a first-in-class, selectve small molecule inhibitor of the single-strand DNA cytosine deaminase APOBEC3G with IC50 of 9.1 uM.

MN58b is a potent, selective choline kinase α (ChoKα) inhibitor with IC50 of 1.4 uM, >30-fold selectivity over ChoKβ and does not affect MAPKs, PI3Ks, and other enzymes involved in the regulation of phospholipid metabolism.

MNK inhibitor 9 is a potent, selective MAPK-interacting kinase (MNK1 and MNK2) inhibitor with IC50 of 3 nM for both, with no activity aginst CDK1/2 (IC50>25 uM).

MNKI-19 is a potent and dual-specific Mnk inhibitor with Ki of 186 nM and 68 nM for Mnk1 and Mnk2, respectively.

MNKI-85 is a potent and selective Mnk2 inhibitor with Ki of 31 nM, displays no inhibitory activities against Mnk1, CDK2A, CDK9T, and CDK4D.

MNKI-8e (MNK inhibitor 8e) is a potent, selective MNK inhibitor that inhibits Mnk2 with Ki of 0.37 uM, displays >34-fold and 4-fold over CDK2 (Ki>10 uM) and CDK9 (Ki=1.66 uM).

MNK-IN-54 is a potent, orally bioavailable dual MNK1/2 and BCR-ABL1 inhibitor with IC50 of 20/10/200/10 nM for Abl T315I/ wt Abl/MNK1/MNK2, respectively.

Moexipril HCl is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure.

Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses.

Monomethylauristatin F(MMAF) is an antitubulin agent that inhibit cell division by blocking the polymerization of tubulin; lower cytotoxic activity than MMAE; antibody drug cytotoxin.

Monooctyl succinate is a monoester, which can be used as a surfactants and a potential fragrance releaser.

Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Mosedipimod (EC-18, 1-palmitoyl-2-linoleoyl-3-acetylglycerol) is a synthetic monoacetyldiaglyceride that stimulates T cell production of IL-2, IL-4, IL-12, IFN-γ, and GM-CSF in vitro.

Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.

Moxifloxacin(Avelox, Avalox) is a fourth generation synthetic fluoroquinolone antibacterial agent.

Mozavaptan (OPC31260) is a orally effective, nonpeptide vasopressin V2 receptor antagonist with an IC50 of 14 nM.

MP-A08 is a first-in-class, highly selective, ATP competitive sphingosine kinase (SphK) inhibitor (Ki of 6.9/27 uM for SK2/SK1).

MPC-0767 (MPC0767, MPC3100 mesylate hydrate) is an L-alanine ester prodrug of MPC-3100, which is a potent, selective, orally bioavailable Hsp90 inhibitor with IC50 of 0.14 uM.

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.

mPGES1-IN-16 is a potent and selective mPGES-1 inhibitor with IC50 of 1 nM.

mPGES1-IN-17d is a potent, selective mPGES-1 inhibitor with enzyme IC50 of 8 nM, A549 cell IC50 of 16.24 nM, human whole blood IC50 of 249.9 nM.

MP-HJ-1b is a novel potent inhibitor of microtubule and tumor cell growth, binds the colchicine pocket at the intra-dimer interface, depolymerizes microtubules and affects spindle formation.

MPI_5a is a potent selective inhibitor of HDAC6, and poorly blocks other HDAC enzymes.

Mps1-IN-3 is a selective and highly potent Mps1 kinase inhibitor with IC50 of 50 nM.

MPT0E028 is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA.

MPT0G211 is a novel potent, selective HDAC6 inhibitor with IC50 of 0.291 nM, displays >1,000-fold selectivity over other HDAC isoforms.

MPTP HCl induced reduction in the DOPAC HVA/dopamine (DA) ratio and increase in striatal ascorbate (AS) oxidation in rats

MRK003 is a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

MRK-560 is a potent, brain-penetrant and orally bioavailable γ-secretase inhibitor that inhibits proteolytic cleavage of APP over the Notch pathway.

MRK-623 is a potent, α2/α3 subunit functionally selectiviie GABAA receptor agonist..

MRK-696 is a non-selective benzodiazepine receptor partial agonist..

MRK-A is a potent, highly selective, brain penetrant inhibitor of mutant IDH1 with IC50 of 5 nM, displays a 10,000-fold mutant to wildtype selectivity ratio.

MRL-1237 is a potent and selective inhibitor of the replication of Enteroviruses with EC50 of 1-10 uM, targets the nonstructural 2C protein.

MRL20 is a novel synthetic PPARγ ligand and orthosteric agonist with canonical LBP binding affinity of 2 nM.

MRL-871 (MRL871) is a potent, selective inhibitor of RORγt via allosteric inverse agonism, inhibits coactivator binding with IC50 of 7 nM; significantly reduces the IL17a mRNA levels in EL4 murine lymphoblast cell line at 10 uM.

MRS 1845 is a potent calcium channel protein inhibitor and inhibits capacitative Ca2+ influx in HL-60 cells (IC50 = 1.7 mM).

MRS 2179 is a potent, selective, competitive P2Y1 receptor antagonist with Kb of 100 nM.

MRS 2179 is a potent, selective, competitive P2Y1 receptor antagonist with Kb of 100 nM.

MRS 2481 is a potent, reversible Aβ42 neurotoxicity inhibitor with ID50 of 500 nM, potently blocks the Aβ calcium channel and protects neurons from Aβ toxicity.

MRS 2485 is a potent, irreversible Aβ42 neurotoxicity inhibitor with ID50 of 500 nM, potently blocks the Aβ calcium channel and protects neurons from Aβ toxicity..

MRS1177 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 0.3 nM.

MRS1186 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 7.66 nM.

MRS1754 is a selective adenosine A2B receptor antagonist (Ki values are 1.97, 16.8, 403, 503, 570 and 612 nM for hA2B, rA1, hA1, hA2A, hA3 and rA2A receptors respectively).

MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.

MRS4458 is a potent, highly specific amtagonist of P2Y14 receptor with IC50 of 169 nM, does not display extensive off-target interactions with biogenic amine receptors..

MRS4478 is a potent, highly specific amtagonist of P2Y14 receptor with IC50 of 269 nM, does not display extensive off-target interactions with biogenic amine receptors..

MRT 199665 is a potent salt-inducible kinases (SIKs) inhibitor with IC50 of 110, 12, 43 nM for SIK1,2,3 respectively.

MRT67307 is a potent and dual IKKϵ and TBK1 inhibitor with IC50 of 160 and 19 nM, respectively.

MRT-83 hydrochloride is a potent Smoothened antagonist that blocks Hedgehog (Hh) signaling in various assays with IC50 of 10 nM.

MRT-83 is a potent antagonist of Smo, with an IC50 in the nanomolar range.

MRTX1257 (MRTX-1257, MRTX 1257) is a potent, selective, covalent and irreversible inhibitor of KRAS G12C, inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 0.9 nM.

MS012 is a potent and selective inhibitor of G9a-Like Protein (GLP) lysine methyltransferase with IC50 of 7 nM, shows >30-fold selectivity for GLP over G9a and other methyltransferases..

MS-0124 is a potent and selective inhibitor of G9a-like Protein (GLP) lysine methyltransferase with IC50 of 13 nM, shows >30-fold selectivity for GLP over G9a and other methyltransferases..

MS2734 is a bisubstrate Nicotinamide N-methyltransferase (NNMT) with IC50 of 14 uM, Kd of 2.7 uM..

MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 µM).

MS-377 is a potent, selective sigma-1 receptor ligand with Kd of 15.2 nM, showed anti-phencyclidine (PCP), anti-dopaminergic and anti-serotonergic activities.

MS402 is a BD1-selective BET BrD inhibitor with Kis of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice.

MS4077 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=3 nM).

MS4078 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=11 nM).

MS645 (MS-645) is a novel, bivalent bromodomain (BRD) inhibitor with Ki of 18.4 nM for tandem BD1-BD2 (BRD4 BD1/BD2 ), shows12- to 28-fold gain in affinity for binding to the tandem BD1-BD2 over the single BD1 or BD2.

MS7972 is a small molecules that blocks p53 and CREB binding protein (CBP) association.

MsbA inhibitor 1 is a novel small molecule lipopolysaccharide biogenesis inhibitor, inhibits MsbA, an ATP-dependent flippase that translocates LPS across the inner membrane; causes mislocalization of LPS to the cell interior, inhibits Δ5 strain with MIC o

MSC1094308 (MSC 1094308) is a reversible, allosteric inhibitor of the type II AAA ATPase human ubiquitin-directed unfoldase (VCP)/p97 and the type I AAA ATPase VPS4B with IC50 of 7.2 and 0.71 uM, respectively.

MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.

MSN-125 (MSN 125, MSN125) is a small molecule Bax inhibitor that inhibits Bax/Bak oligomerization and prevents mitochondrial outer membrane permeabilization (MOMP) with IC50 of 4 uM.

MST312 is a telomerase inhibitor (IC50 = 0.67 μM in a TRAP assay).

MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM).

MtbHU-IN-1 is an inhibitor of Mycobacterium tuberculosis nucleoid-associated protein HU (MtbHU), with a Kd of 98 nM for binding to WT MtbHU.

MTEP Hcl is a potent, selective and non-competitive mGlu5 antagonist with IC50 and Ki of 5 nM and 16 nM, respectively.

MTI31 (LXI-15029, mTOR inhibitor-31) is a novel potent, selective mTORC1/mTORC2 inhibitor with Kd of 0.2 nM (mTOR), displays >5,000-fold selectivity over PIK3CA, PIK3CB and PIK3G.

Mtphagy Dye is a small-molecule fluorescent probe for visualizing mitophagy.

MU1210 (MU-1210) is a potent and highly selective inhibitor of cdc-like kinases (CLKs) with IC50 of 51 nM (cellular BRET for CLK1).

MU1300 (MU-1300) is novel effective, selective modulator of the Hedgehog (Hh) pathway, suppresses Hh-dependent osteogenesis with IC50 of 300 nM in osteoblast differentiation assay using C3H10T1/2 cells, targets and binds to Smoothened (Smo) directly.

Mubritinib is a potent inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase.

Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an IC50 value being 1.8 ±1.5 μM.

MUT-A is a novel potent, HIV-1 Integrase IN-LEDGF allosteric inhibitor, shows potent anti-HIV activity with EC50 of 32 nM and 12 nM for NL4-3 or HxB2 HIV-1 strains, respectively.

mutant EGFR inhibitor B30 is a potent, selective, next-generation EGFR mutants inhibitor with IC50 of 1.1 and 7.2 nM for EGFRL858R and EGFRL858R/T790M/C797S, respectively.

mutant IDH1 inhibitor VVS is a potent, selective mutant IDH1 inhibitor with nanomolar potency against both IDH1 R132H and IDH1 R132C, efficiently suppresses the cell-based production of D-2-HG in an HEK293 mutant embryonic kidney cell line..

MW150 (MW01-18-150SRM) is a selective, brain penetrant p38αMAPK, which is efficacious in diverse animal models of neurologic disorders.

MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM

MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM

MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM, no affitnity for CK1δ.